Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease

Next Previous
Search
Trial Profile

A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Narsoplimab (Primary) ; Narsoplimab (Primary)
  • Indications IgA nephropathy; Lupus nephritis; Membranoproliferative glomerulonephritis; Membranous glomerulonephritis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Omeros Corporation

    • Most Recent Events

    • 01 Mar 2022 According to an Omeros Corporation media release, data were presented in the World Congress of Nephrology meeting 2022.
    • 05 Nov 2021 According to an Omeros Corporation media release, data from this study are also being prepared for submission to a peer-reviewed journal.
    • 05 Nov 2021 Long-term follow-up ( 3 Years) results presented in an Omeros Corporation media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top